ZANTAC INJECTION PREMIXED Rx
Generic Name and Formulations:
Ranitidine (as HCl) 1mg/mL in sodium chloride 0.45%; IV infusion; preservative-free.
Indications for ZANTAC INJECTION PREMIXED:
Hospitalized patients with pathological hypersecretory conditions, intractable duodenal ulcer. Short-term alternative to oral therapy.
For slow IV drip only. >16yrs: Intermittent infusion: 50mg every 6–8hrs (infuse over 15–20min); usual max 400mg/day. Continuous IV infusion, or for Zollinger-Ellison: see literature. Renal impairment (CrCl<50mL/min): 50mg every 18–24hrs or more often if needed (intermittent only). Coincide a dose for end of hemodialysis.
<1month: not recommended. ≥1month–16yrs: Treatment of duodenal ulcer: 2–4mg/kg per day in divided doses every 6–8hrs; max 50mg every 6–8hrs.
History of acute porphyria: not recommended. Renal impairment: reduce dose. Hepatic dysfunction. Discontinue if hepatic disorders occur. Monitor SGPT if on high-dose IV therapy for ≥5 days. Pregnancy (Cat.B). Nursing mothers.
May increase triazolam, midazolam, glipizide, procainamide levels. May decrease ketoconazole, atazanavir, delaviridine, gefitnib levels. Monitor anticoagulants. May cause false (+) urine protein test with Multistix.
Headache, GI disturbances, jaundice, hepatitis, rash; rare: CNS disturbances, arrhythmias, blurred vision, arthralgia, myalgia, inj site reactions, blood dyscrasias, anaphylaxis, angioneurotic edema, acute interstitial nephritis, bradycardia with rapid administration (IV); increased risk of pneumonia (see literature).
Tabs 150mg—60, 180, 500; 300mg—30; EFFERdose tabs—60; Syrup—pt; Inj single dose 2mL—10; Multidose 6mL—1; Premixed 50mL—24
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma